Clopidogrel and Ginkgo: Can You Take Them Together?

Moderate — Timing Mattersconflict
Learn about each ingredient:ClopidogrelGinkgo

Quick answer

Ginkgo biloba inhibits platelet-activating factor and may add to clopidogrel's blockade of the platelet P2Y12 ADP receptor. While a healthy-volunteer study did not detect additive platelet inhibition, observational and case-report data link the combination to increased bleeding, including intracranial hemorrhage.

Avoid taking ginkgo while on clopidogrel. If you choose to combine them, do so only with your prescriber's approval, use a standardized extract at the lowest dose, and watch closely for bruising or bleeding.

What happens when you take clopidogrel with ginkgo?

Clopidogrel (Plavix) is a prodrug that, once activated by liver enzymes (mainly CYP2C19), irreversibly blocks the P2Y12 ADP receptor on platelets. This prevents ADP-mediated platelet activation and aggregation for the life of the platelet (about 7 to 10 days). It is widely used after coronary stenting, after stroke, and in peripheral arterial disease.

Ginkgo biloba leaf extract contains terpene lactones (especially ginkgolide B), which inhibit platelet-activating factor (PAF) and contribute mild antiplatelet activity through a different pathway than P2Y12 blockade.

A healthy-volunteer pharmacodynamic study in 2007 (Thrombosis Research) found that adding ginkgo to clopidogrel did not measurably enhance platelet inhibition beyond clopidogrel alone in young healthy participants. But case reports and observational analyses tell a more cautious story: combination use has been linked to bleeding events including subdural hematoma, spontaneous hyphema, and post-procedure bleeding.

Why is this important?

Patients on clopidogrel are usually there because they need robust antiplatelet protection: coronary artery stents (where stent thrombosis is catastrophic), recent ischemic stroke, or peripheral arterial disease. Many are also on aspirin as part of dual antiplatelet therapy, which already roughly doubles the bleeding risk compared with either drug alone. Adding ginkgo on top of that can tip a patient over the bleeding threshold.

A 2025 PLOS One analysis specifically identified clopidogrel as one of the antiplatelet drugs most commonly involved in ginkgo-related bleeding interactions, with clinically significant bleeding events reported. The discrepancy between healthy-volunteer studies (which often show no detectable interaction) and real-world reports (which show clear bleeding signals) reflects the fact that real patients are older, sicker, on multiple bleeding-risk drugs, and exposed for months or years rather than days.

Many patients underestimate ginkgo because it is sold over the counter and marketed as a memory or circulation supplement. They may not think of it as a drug at all and may not mention it during medication reviews.

What should you do?

If you are on clopidogrel, the safest default is to avoid ginkgo. The benefits of ginkgo for memory, dementia prevention, or tinnitus are modest and inconsistent in clinical trials, and the cost of an avoidable bleed on dual antiplatelet therapy can be major.

If you and your prescriber agree that ginkgo is worth trying, use only a standardized extract such as EGb 761 at no more than 240 mg per day, and set a clear timeline to evaluate whether it is helping. Stop ginkgo at least 7 to 10 days before any planned surgery, dental procedure, biopsy, colonoscopy, or epidural injection.

Know the bleeding warning signs and act on them: unusual bruising, prolonged bleeding from minor cuts, persistent nosebleeds, bleeding gums, pink or red urine, black tarry stools, coughing or vomiting blood, severe sudden headache, vision changes, or sudden one-sided weakness or speech changes. Any of these warrant immediate evaluation.

Which specific products are affected?

This applies to clopidogrel under any brand name (Plavix) at any dose (75 mg daily standard, 300 to 600 mg loading doses). The same considerations broadly apply to the other P2Y12 inhibitors prasugrel (Effient) and ticagrelor (Brilinta), and to other antiplatelet agents including aspirin and cilostazol.

On the ginkgo side, this covers standardized leaf extracts (EGb 761, GBE 24/6, Tebonin, Tanakan, Rokan), ginkgo teas, tinctures, and combination memory, brain-health, tinnitus, and circulation formulas. Ginkgo often appears in proprietary nootropic blends without being highlighted on the front label.

The bottom line

The healthy-volunteer pharmacology data on ginkgo plus clopidogrel are reassuring, but real-world reports of bleeding tell a more cautious story, especially in older patients and those on dual antiplatelet therapy. If you take clopidogrel, the simplest move is to skip ginkgo. If you choose to combine them, do so deliberately, at the lowest effective ginkgo dose, with your prescriber's approval, and with a clear plan for stopping before any procedure.

References

Primary evidence for this article. Always consult your healthcare provider for personal medical advice.

Related Interactions

Other interactions you should know about

Aspirin + Ginkgo

moderate

Ginkgo biloba can inhibit platelet-activating factor (PAF) and platelet aggregation, which can add to aspirin's irreversible inhibition of cyclooxygenase-1 and thromboxane A2. The combination may modestly increase minor bleeding events, with case reports of more serious bleeds in vulnerable patients.

Warfarin + Ginkgo

high

Ginkgo biloba inhibits platelet-activating factor and can prolong bleeding time, adding an antiplatelet effect on top of warfarin's vitamin-K-antagonist anticoagulation. A 2025 PLOS One analysis of 2,647 prescriptions found ginkgo co-prescription was associated with a significantly higher rate of bleeding adverse events (hazard ratio ~1.38) and abnormal coagulation profiles.

Rivaroxaban + Ginkgo

moderate

Ginkgo biloba has antiplatelet properties and may theoretically add to the bleeding risk of rivaroxaban, although a controlled pharmacokinetic study with EGb 761 found no change in rivaroxaban plasma levels or anti-Factor Xa activity. The risk is primarily additive rather than pharmacokinetic.

Warfarin + Dong Quai

high

Dong quai (Angelica sinensis) contains coumarin derivatives (ferulic acid, osthole) and has documented antiplatelet activity. A widely cited case report (Page & Lawrence, Pharmacotherapy 1999, PMID 10417036) described a woman whose INR rose to 4.9 within four weeks of adding dong quai 565 mg once to twice daily to stable warfarin.

Warfarin + Turmeric

high

Curcumin, the main active in turmeric, has antiplatelet activity and may also inhibit CYP2C9 metabolism of warfarin, raising warfarin levels. New Zealand Medsafe issued an alert in 2018 after a patient's INR rose above 10 within weeks of starting a turmeric/curcumin product on previously stable warfarin therapy.

Warfarin + Feverfew

moderate

Feverfew (Tanacetum parthenium) inhibits platelet aggregation in vitro via its parthenolide sesquiterpene lactones. There are no robust human case reports of bleeding with warfarin specifically, but standard herbal-interaction references (StatPearls, Australian Prescriber) recommend avoidance based on the pharmacologic plausibility of additive bleeding risk.

Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before making changes to your supplement or medication routine. Pilora does not diagnose, treat, cure, or prevent any disease.

Check all your supplement interactions instantly

Try Pilora Free